Skip to main content
    A

    Ardelyx Inc (ARDX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.07
    -0.02 (-0.65%)

    Market Cap: $776.74M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Ardelyx Inc (ARDX) Earnings: Report Dates and Results

    Updated Nov 3, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Ardelyx reported EPS of $0.00, above the -$0.02 estimate. It beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    59%(23/39)
    Avg Surprise
    +25.91%
    Streak
    1 Q

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus$0.04
    Range$0.02 - $0.06
    13 analysts
    Revenue Consensus
    $142.01M
    Range$127.28M - $155.98M
    13 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus-$0.05
    Range-$0.08 - -$0.02
    4 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.02-133.3%
    60d ago-$0.03-61.5%
    30d ago-$0.04-50.0%
    7d ago-$0.04-50.0%
    Current-$0.05
    Revenue Consensus
    $115.82M
    Range$101.60M - $122.17M
    6 analysts

    Next Report

    ARDX's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    ARDX Earnings Call

    The latest ARDX earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, ARDX beat 23, missed 13 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $127.66M, up 15.7% from $110.33M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.00-$0.02-$0.06 - $0.02+100.00%BeatN/A80 up, 1 downNov 3, 2026$127.66M
    Jun 30, 2026-$0.07-$0.05-$0.06 - -$0.03-40.00%MissN/A70 up, 4 downAug 6, 2026$120.88M
    Mar 31, 2026-$0.15-$0.14-$0.16 - -$0.11-7.14%MissN/A71 up, 0 downApr 30, 2026$94.47M
    Dec 31, 2025$0.00-$0.02N/A+91.37%Beat-108.5%70 up, 1 downFeb 19, 2026$125.22M
    Sep 30, 2025$0.00-$0.07-$0.09 - -$0.01+94.29%BeatN/A73 up, 0 downOct 30, 2025$110.33M
    Jun 30, 2025-$0.08-$0.14-$0.17 - -$0.11+42.86%BeatN/A60 up, 0 downAug 4, 2025$97.66M
    Mar 31, 2025-$0.17-$0.07-$0.14 - -$0.04-142.86%MissN/A42 up, 0 downMay 1, 2025$74.11M
    Dec 31, 2024$0.02$0.00-$0.04 - $0.02N/AN/AN/A46 up, 0 downFeb 20, 2025$116.13M
    Sep 30, 2024$0.00-$0.05-$0.08 - -$0.01+93.20%Beat-111.3%101 up, 0 downOct 31, 2024$98.24M
    Jun 30, 2024-$0.07-$0.11-$0.14 - -$0.06+36.36%BeatN/A102 up, 1 downAug 1, 2024$73.22M
    Mar 31, 2024-$0.11-$0.16-$0.25 - -$0.12+31.25%BeatN/A100 up, 1 downMay 2, 2024$46.02M
    Dec 31, 2023-$0.12-$0.09-$0.13 - -$0.04-33.33%Miss-300.0%91 up, 0 downFeb 22, 2024$34.36M
    Sep 30, 2023$0.03-$0.11-$0.15 - -$0.06+127.27%BeatN/A80 up, 0 downOct 31, 2023$56.39M
    Jun 30, 2023-$0.08-$0.11-$0.12 - -$0.10+27.27%BeatN/A71 up, 0 downAug 2, 2023$22.33M
    Mar 31, 2023-$0.13-$0.10-$0.12 - -$0.08-30.00%MissN/A61 up, 0 downMay 3, 2023$11.37M
    Dec 31, 2022$0.06-$0.02-$0.17 - $0.10+400.00%BeatN/A60 up, 0 downMar 2, 2023$44.18M
    Sep 30, 2022-$0.14-$0.17-$0.19 - -$0.14+17.65%BeatN/A71 up, 0 downNov 3, 2022$4.99M
    Jun 30, 2022-$0.19-$0.20-$0.21 - -$0.17+5.00%BeatN/A70 up, 0 downAug 4, 2022$2.53M
    Mar 31, 2022-$0.21-$0.23-$0.27 - -$0.18+8.70%BeatN/A70 up, 0 downMay 5, 2022$468000
    Dec 31, 2021-$0.31-$0.30-$0.50 - -$0.18-3.33%MissN/A60 up, 0 downFeb 28, 2022$1.03M
    Sep 30, 2021-$0.42-$0.35-$0.48 - -$0.25-20.00%MissN/A7N/ANov 12, 2021$1.17M
    Jun 30, 2021-$0.45-$0.37-$0.40 - -$0.35-21.62%MissN/A7N/AAug 13, 2021$1.31M
    Mar 31, 2021-$0.34-$0.34-$0.38 - -$0.300.00%In lineN/A7N/AMay 6, 2021$6.58M
    Dec 31, 2020-$0.32-$0.26-$0.28 - -$0.24-23.08%MissN/A6N/AMar 8, 2021$1.81M
    Sep 30, 2020-$0.20-$0.30-$0.31 - -$0.26+33.33%BeatN/A6N/ANov 5, 2020$2.71M
    Jun 30, 2020-$0.28-$0.25-$0.29 - -$0.22-12.00%MissN/A6N/AAug 6, 2020$1.84M
    Mar 31, 2020-$0.25-$0.25-$0.31 - -$0.220.00%In lineN/A6N/AMay 7, 2020$1.21M
    Dec 31, 2019-$0.27-$0.33-$0.37 - -$0.30+18.18%BeatN/A6N/AMar 6, 2020$2.23M
    Sep 30, 2019-$0.37-$0.37-$0.40 - -$0.320.00%In lineN/A5N/ANov 6, 2019$3.01M
    Jun 30, 2019-$0.41-$0.38-$0.40 - -$0.37-7.89%MissN/A4N/AAug 9, 2019$36000
    Mar 31, 2019-$0.42-$0.39-$0.44 - -$0.35-7.69%MissN/A5N/AMay 7, 2019N/A
    Dec 31, 2018-$0.45-$0.41-$0.47 - -$0.36-9.76%Miss-314.3%4N/AMar 6, 2019$55000
    Sep 30, 2018-$0.39-$0.43-$0.47 - -$0.37+9.30%BeatN/A5N/ANov 7, 2018$172000
    Jun 30, 2018-$0.42-$0.44-$0.47 - -$0.38+4.55%BeatN/A6N/AAug 7, 2018$60000
    Mar 31, 2018-$0.36-$0.46-$0.50 - -$0.39+21.74%BeatN/A5N/AMay 8, 2018$2.32M
    Dec 31, 2017$0.21-$0.41-$0.53 - -$0.10+151.22%BeatN/A7N/AMar 14, 2018$42.00M
    Sep 30, 2017-$0.44-$0.54-$0.56 - -$0.48+18.52%BeatN/A7N/ANov 7, 2017N/A
    Jun 30, 2017-$0.54-$0.65-$0.67 - -$0.62+16.92%BeatN/A6N/AAug 9, 2017N/A
    Mar 31, 2017-$0.59-$0.67N/A+11.94%BeatN/AN/AN/AMay 5, 2017N/A
    Dec 31, 2016-$0.66-$0.72N/A+8.33%BeatN/AN/AN/AFeb 17, 2017N/A
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.26, after -$0.16 the year before. It was -$2.84 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.26N/A
    Dec 31, 2024-$0.16N/A
    Dec 31, 2023-$0.30N/A
    Dec 31, 2022-$0.48N/A
    Dec 31, 2021-$1.52N/A
    Dec 31, 2020-$1.05N/A
    Dec 31, 2019-$1.47N/A
    Dec 31, 2018-$1.62N/A
    Dec 31, 2017-$1.36N/A
    Dec 31, 2016-$2.84N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,800 words across 15 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,84415
    2026Q2Jun 30, 20264,79813
    2026Q1Mar 31, 20268,05615
    2025Q4Dec 31, 20258,60417
    2025Q3Sep 30, 20256,54815
    2025Q2Jun 30, 20257,12216
    2025Q1Mar 31, 20256,14813
    2024Q4Dec 31, 20247,07314

    2026Q3 Earnings Call

    Opening remarks

    Lisa Caperelli SVP, Investor Relations and Corporate Communications Thank you, Paul. Good afternoon, and welcome to our third quarter 2026 financial results and business update call. Earlier today, we issued our earnings release, which can be found in the Investors section of our website at ardelyx.com. Slides that accompany today's call can also be found on our website. On today's call, I am joined by Mike Raab, President and CEO of Ardelyx, and Sue Hohenleitner, our Chief Financial Officer. Before we begin, I'd like to remind you that some of the statements made during the call today are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties that may cause our actual results to differ materially from those expressed or implied, including those described in our annual report on Form 10-K, our quarterly report on Form 10-Q, which was filed today, and from time to time in our other documents filed with the SEC. These forward-looking statements speak only as of today's date. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our views change. I will now pass the call over to Mike. Mike?

    Michael Raab President and CEO Thank you, Lisa. Good afternoon, everyone, and thank you for joining us today. Ardelyx is a company focused on developing and commercializing innovative medicines. Today, with IBSRELA and XPHOZAH, we have two first-in-class medicines that in the third quarter generated over $125 million in revenue, up 19% from a year ago. With a strengthened financial position and a robust patent portfolio, our products are well positioned for significant long-term growth. Our focus is now to leverage that foundation and build a pipeline to create long-term value. Our third quarter performance bolsters our confidence as we focus on executing on our priorities: accelerating the growth of IBSRELA, maintaining XPHOZAH's momentum, building and expanding our pipeline, and delivering strong financial results. Starting with IBSRELA. In Q3, IBSRELA generated revenue of $96.3 million, representing 23% year-over-year growth. HCP confidence in IBSRELA remains high, with demand reaching all-time highs as the number of total writers, total prescriptions, and market share continues to grow. This growth supports our full-year guidance and reinforces our long-term view of achieving $1 billion in annual revenue. Critical to that is our ongoing work to thoughtfully eliminate the payer friction HCPs and patients experience when first starting IBSRELA. In our efforts to alleviate some of this friction in the third quarter, we began to see progress that gave us confidence these initiatives are beginning to take hold. As we've noticed in the past, IBSRELA is a promotionally sensitive brand.

    Frequently Asked Questions About ARDX

    Did ARDX beat earnings estimates last quarter?

    Yes. Ardelyx reported EPS of $0.00 for the quarter ended Sep 30, 2026, above the -$0.02 estimate, a 100.00% surprise.

    What EPS do analysts expect from ARDX next quarter?

    The consensus EPS estimate for Ardelyx for the quarter ending Dec 31, 2026 is $0.04 from 13 analysts, with estimates from $0.02 to $0.06.

    How often does ARDX beat earnings estimates?

    Ardelyx beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate, with an average surprise of +28.96%.